Literature DB >> 24100493

Effects of substitutions at the 4' and 2 positions on the bioactivity of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.

Karen A Kirby1, Eleftherios Michailidis, Tracy L Fetterly, Musetta A Steinbach, Kamalendra Singh, Bruno Marchand, Maxwell D Leslie, Ariel N Hagedorn, Eiichi N Kodama, Victor E Marquez, Stephen H Hughes, Hiroaki Mitsuya, Michael A Parniak, Stefan G Sarafianos.   

Abstract

Nucleos(t)ide reverse transcriptase inhibitors (NRTIs) form the backbone of most anti-HIV therapies. We have shown that 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) is a highly effective NRTI; however, the reasons for the potent antiviral activity of EFdA are not well understood. Here, we use a combination of structural, computational, and biochemical approaches to examine how substitutions in the sugar or adenine rings affect the incorporation of dA-based NRTIs like EFdA into DNA by HIV RT and their susceptibility to deamination by adenosine deaminase (ADA). Nuclear magnetic resonance (NMR) spectroscopy studies of 4'-substituted NRTIs show that ethynyl or cyano groups stabilize the sugar ring in the C-2'-exo/C-3'-endo (north) conformation. Steady-state kinetic analysis of the incorporation of 4'-substituted NRTIs by RT reveals a correlation between the north conformation of the NRTI sugar ring and efficiency of incorporation into the nascent DNA strand. Structural analysis and the kinetics of deamination by ADA demonstrate that 4'-ethynyl and cyano substitutions decrease the susceptibility of adenosine-based compounds to ADA through steric interactions at the active site. However, the major determinant for decreased susceptibility to ADA is the 2-halo substitution, which alters the pKa of N1 on the adenine base. These results provide insight into how NRTI structural attributes affect their antiviral activities through their interactions with the RT and ADA active sites.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24100493      PMCID: PMC3837839          DOI: 10.1128/AAC.01703-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  60 in total

Review 1.  Biochemical and mechanistic basis for the activity of nucleoside analogue inhibitors of HIV reverse transcriptase.

Authors:  George R Painter; Merrick R Almond; Shuli Mao; Dennis C Liotta
Journal:  Curr Top Med Chem       Date:  2004       Impact factor: 3.295

2.  Adenosine deaminase prefers a distinct sugar ring conformation for binding and catalysis: kinetic and structural studies.

Authors:  H Ford; F Dai; L Mu; M A Siddiqui; M C Nicklaus; L Anderson; V E Marquez; J J Barchi
Journal:  Biochemistry       Date:  2000-03-14       Impact factor: 3.162

Review 3.  Antiviral therapies: focus on hepatitis B reverse transcriptase.

Authors:  Eleftherios Michailidis; Karen A Kirby; Atsuko Hachiya; Wangdon Yoo; Sun Pyo Hong; Soo-Ok Kim; William R Folk; Stefan G Sarafianos
Journal:  Int J Biochem Cell Biol       Date:  2012-04-16       Impact factor: 5.085

4.  Fluorine substituted adenosines as probes of nucleobase protonation in functional RNAs.

Authors:  Ian T Suydam; Scott A Strobel
Journal:  J Am Chem Soc       Date:  2008-09-20       Impact factor: 15.419

5.  The sugar ring conformation of 4'-ethynyl-2-fluoro-2'-deoxyadenosine and its recognition by the polymerase active site of HIV reverse transcriptase.

Authors:  K A Kirby; K Singh; E Michailidis; B Marchand; E N Kodama; N Ashida; H Mitsuya; M A Parniak; S G Sarafianos
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  2011-02-12       Impact factor: 1.770

6.  Primary structure of bovine adenosine deaminase.

Authors:  M A Kelly; M M Vestling; C M Murphy; S Hua; T Sumpter; C Fenselau
Journal:  J Pharm Biomed Anal       Date:  1996-08       Impact factor: 3.935

7.  Mechanism of interaction of human mitochondrial DNA polymerase γ with the novel nucleoside reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine indicates a low potential for host toxicity.

Authors:  Christal D Sohl; Kamlendra Singh; Rajesh Kasiviswanathan; William C Copeland; Hiroaki Mitsuya; Stefan G Sarafianos; Karen S Anderson
Journal:  Antimicrob Agents Chemother       Date:  2011-12-12       Impact factor: 5.191

Review 8.  Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity.

Authors:  T N Kakuda
Journal:  Clin Ther       Date:  2000-06       Impact factor: 3.393

9.  Mechanism of inhibition of HIV-1 reverse transcriptase by 4'-Ethynyl-2-fluoro-2'-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor.

Authors:  Eleftherios Michailidis; Bruno Marchand; Eiichi N Kodama; Kamlendra Singh; Masao Matsuoka; Karen A Kirby; Emily M Ryan; Ali M Sawani; Eva Nagy; Noriyuki Ashida; Hiroaki Mitsuya; Michael A Parniak; Stefan G Sarafianos
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

Review 10.  Anti-HIV drugs.

Authors:  E De Clercq
Journal:  Verh K Acad Geneeskd Belg       Date:  2007
View more
  19 in total

1.  Oral administration of the nucleoside EFdA (4'-ethynyl-2-fluoro-2'-deoxyadenosine) provides rapid suppression of HIV viremia in humanized mice and favorable pharmacokinetic properties in mice and the rhesus macaque.

Authors:  Cheryl A Stoddart; Sofiya A Galkina; Pheroze Joshi; Galina Kosikova; Mary E Moreno; Jose M Rivera; Barbara Sloan; Aaron B Reeve; Stefan G Sarafianos; Michael Murphey-Corb; Michael A Parniak
Journal:  Antimicrob Agents Chemother       Date:  2015-05-04       Impact factor: 5.191

2.  Probing the molecular mechanism of action of the HIV-1 reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) using pre-steady-state kinetics.

Authors:  Yagmur Muftuoglu; Christal D Sohl; Andrea C Mislak; Hiroaki Mitsuya; Stefan G Sarafianos; Karen S Anderson
Journal:  Antiviral Res       Date:  2014-03-12       Impact factor: 5.970

3.  CMCdG, a Novel Nucleoside Analog with Favorable Safety Features, Exerts Potent Activity against Wild-Type and Entecavir-Resistant Hepatitis B Virus.

Authors:  Nobuyo Higashi-Kuwata; Sanae Hayashi; Debananda Das; Satoru Kohgo; Shuko Murakami; Shin-Ichiro Hattori; Shuhei Imoto; David J Venzon; Kamalendra Singh; Stefan G Sarafianos; Yasuhito Tanaka; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

4.  HIV pre-exposure prophylaxis for women and infants prevents vaginal and oral HIV transmission in a preclinical model of HIV infection.

Authors:  Martina Kovarova; Uma Shanmugasundaram; Caroline E Baker; Rae Ann Spagnuolo; Chandrav De; Christopher C Nixon; Angela Wahl; J Victor Garcia
Journal:  J Antimicrob Chemother       Date:  2016-08-01       Impact factor: 5.790

5.  Structural basis of HIV inhibition by translocation-defective RT inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA).

Authors:  Zhe Li Salie; Karen A Kirby; Eleftherios Michailidis; Bruno Marchand; Kamalendra Singh; Lisa C Rohan; Eiichi N Kodama; Hiroaki Mitsuya; Michael A Parniak; Stefan G Sarafianos
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-03       Impact factor: 11.205

6.  SAMHD1 has differential impact on the efficacies of HIV nucleoside reverse transcriptase inhibitors.

Authors:  Andrew D Huber; Eleftherios Michailidis; Megan L Schultz; Yee T Ong; Nicolin Bloch; Maritza N Puray-Chavez; Maxwell D Leslie; Juan Ji; Anthony D Lucas; Karen A Kirby; Nathaniel R Landau; Stefan G Sarafianos
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

7.  MK-8591 (4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine) Exhibits Potent Activity against HIV-2 Isolates and Drug-Resistant HIV-2 Mutants in Culture.

Authors:  Vincent H Wu; Robert A Smith; Sara Masoum; Dana N Raugi; Selly Ba; Moussa Seydi; Jay A Grobler; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

8.  Physiological Mg2+ Conditions Significantly Alter the Inhibition of HIV-1 and HIV-2 Reverse Transcriptases by Nucleoside and Non-Nucleoside Inhibitors in Vitro.

Authors:  Vasudevan Achuthan; Kamlendra Singh; Jeffrey J DeStefano
Journal:  Biochemistry       Date:  2016-12-27       Impact factor: 3.162

Review 9.  4'-Ethynyl-2-fluoro-2'-deoxyadenosine, MK-8591: a novel HIV-1 reverse transcriptase translocation inhibitor.

Authors:  Martin Markowitz; Stefan G Sarafianos
Journal:  Curr Opin HIV AIDS       Date:  2018-07       Impact factor: 4.283

10.  4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms.

Authors:  Eleftherios Michailidis; Andrew D Huber; Emily M Ryan; Yee T Ong; Maxwell D Leslie; Kayla B Matzek; Kamalendra Singh; Bruno Marchand; Ariel N Hagedorn; Karen A Kirby; Lisa C Rohan; Eiichi N Kodama; Hiroaki Mitsuya; Michael A Parniak; Stefan G Sarafianos
Journal:  J Biol Chem       Date:  2014-06-26       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.